The Latest Breaking News from Omicron

A timeline of Fauci's predictions about the COVID pandemic

The U.S. is out of a "full-blown explosive pandemic phase" Fauci said this week.

Axios · Apr 27, 2022

Mailbag: Where Will the NFL Draft’s Top Tackles Land?

Will one of the draft’s best blockers be available at No. 5? Plus, Matt Corral’s stock, the Seahawks’ future at QB and more.

Sports Illustrated · Apr 27, 2022

Nine Omicron symptoms affecting fully vaccinated — and two early signs you might have it

Fainting and fatigue may signal onset of Omicron, experts say

The Independent UK · Apr 27, 2022

Most Americans have COVID-19 antibodies as case numbers rise - Roll Call

The percentage of people with antibodies increased from 34 percent in December to roughly 58 percent in February, the CDC said.

Roll Call · Apr 26, 2022

What do we know about the new omicron mutant?

A new omicron mutant that is a descendent of the earlier “stealth omicron” has quickly gained ground in the United States

The Independent UK · Apr 26, 2022

Rise in Covid-19 death registrations despite bank holiday

The rise follows the recent surge in infections driven by the Omicron BA.2 variant.

The Independent UK · Apr 26, 2022

Covid camps, fenced-off apartments and workers forced to sleep in factories — inside Shanghai’s lockdown

More than 25 million residents have been shut inside their homes for four weeks while officials battle to contain the city’s worst Omicron surge to date. As fences go up around housing blocks with no end to the lockdown in sight, Ed Tucker reports from China’s Covid frontline

Evening Standard · Apr 26, 2022

FDA Gives Green Signal To Human Trial For Sorrento's STI-9167 Against Omicron

The FDA has cleared Sorrento Therapeutics Inc's (NASDAQ:SRNE) investigational new drug application (IND) for intravenous (IV) STI-9167 (COVISHIELD) to study the safety and pharmacokinetics in healthy volunteers.  STI-9167 is the IV formulation of the intranasal STI-9199 neutralizing antibody. Also Read: Sorrento To Start Late-Stage Trial Of Abivertinib In Critically-Ill COVID-19 Patients. The Phase 1 study…

Benzinga · Apr 25, 2022

Poland, Moderna Working Towards Increased Flexibility Of COVID-19 Vaccine Contracts: Reuters

Poland can compromise with Moderna Inc (NASDAQ:MRNA) on increasing the flexibility of COVID-19 vaccine contracts, Reuters reported citing the health minister, striking an upbeat tone after initial talks with the company. Poland has said it will not take or pay for more doses of the COVID-19 vaccine under the European Union's supply contract.  Reuters…

Benzinga · Apr 25, 2022

COVID-19 breath tests could be the future of living with the virus, but this pandemic solution has a catch

The US has just approved a new COVID-19 breathalyser test that promises to deliver results within minutes, with no nasal swabs required. Scientists say it could help safeguard big gatherings from becoming superspreader events, but there are still a few kinks to iron out.

ABC News · Apr 25, 2022